ARIA can only last for another 3 to 4 quarters before needing much needed cash to continue. I predict that will have to address that sooner than later by means of selling more stock. I believe their main focus, before anyone is going to be interested in buying, is getting the drug up to the first line therapy. There will be some challenges ahead, that's for sure.